Beam Therapeutics
BEAM
85 hedge funds and large institutions have $727M invested in Beam Therapeutics in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 11 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 10
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
20% more funds holding
Funds holding: 71 → 85 (+14)
3.23% more ownership
Funds ownership: 53.81% → 57.04% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less capital invested
Capital invested by funds: $776M → $727M (-$48.6M)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.9M |
| 2 |
BlackRock
New York
|
+$22.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.85M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.65M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.81M |
Top Sellers
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$20.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10M |
| 4 |
Millennium Management
New York
|
-$9.48M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$8.48M |
BEAM Hedge Fund Activity: Q3 2020 in Review
85 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2020, worth a combined $727M — down 6.3% from $776M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BEAM positions and 11 closed out — a net gain of 14 holders — while 32 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $26.9M. The largest seller was Fidelity International, cutting an estimated $20.1M.
- 85 institutional investors held Beam Therapeutics (BEAM) as of Q3 2020, up from 71 in Q2 2020.
- Funds reported $727M of Beam Therapeutics stock for Q3 2020, down 6.3% quarter-over-quarter.
- 25 funds opened new Beam Therapeutics positions in Q3 2020 and 11 closed out, a net change of +14 holders.
- The largest Beam Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $26.9M added.
- The largest Beam Therapeutics seller in Q3 2020 was Fidelity International, an estimated $20.1M sold.
Based on aggregated 13F filings for Q3 2020.